Drug intelligence / Profile preview

EHT + AGN 0002

Development stage: Preclinical
Lead developer: Allergan
Modality: Small Molecules
Administration: Oral

Overview

EHT + AGN 0002 is a small molecule compound developed as part of a collaboration between ExonHit Therapeutics and Allergan for the potential treatment of neuropathic pain. It serves as a backup compound to the lead candidate EHT/AGN 0001 in their most advanced program, with an orally administered formulation designed to relieve neuropathic pain symptoms through a novel mechanism of action that remains unspecified in available sources. The program involved out-licensing by Allergan to Bristol-Myers Squibb, indicating early-stage development focused on pain therapeutics.[1][3]

Beyond the preview

Go deeper on EHT + AGN 0002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EHT + AGN 0002.

Explore the full profile